U.S., July 16 -- ClinicalTrials.gov registry received information related to the study (NCT07064889) titled 'The Combination of Upadacitinib and High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocytopenia' on July 07.
Brief Summary: Randomized, open-label, multicenter study to compare the efficacy and safety of Upadacitinib plus high-dose dexamethasone compared to high-dose dexamethasone monotherapy for the first-line treatment of adults with primary immune thrombocytopenia (ITP).
Study Start Date: July 30
Study Type: INTERVENTIONAL
Condition:
Immune Thrombocytopenia
Intervention:
DRUG: Dexamethasone
Dexamethasone, 40 mg/d, for 4 days (The 4-day course of dexamethasone was repeated in the case of lack of respons...